Announces

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlights progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises and announces a new development program for postoperative nausea and vomiting (PONV).

Recent Corporate Progress

Pain Management Franchise

  • New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 12, 2021.
  • Low Dose HTX-034 Produced Greater Pain Reduction to Bupivacaine, the Current Standard-of-Care, Through 96 hours in Bunionectomy Study: In the Phase 1b portion

The MITEF Saudi Arabia competitors announces the semi-finalists

The second spherical of judging will be held on February 20, 2021 to announce the names of the finalists (27 groups). The 3rd spherical will be held on March 3, 2021, right after the digital briefing classes and the business accelerator from January 9 to February 13, 2021. Startup Financial investment Forum will be held on March 4, 5 and 6.

On this situation, Bayan Alghamdi, Head – Entrepreneurship Courses & MITEF Saudi at Local community Jameel, mentioned: “This year, the MITEF Saudi Arabia Competitors saw remarkable progress in phrases of the excellent of entries in various groups and fields, such as e-commerce, education systems, customer products and services, productivity apps, in addition to digital technologies and health care. The levels of competition is organised in line with the Kingdom’s Vision 2030 to assist compact and medium enterprises. The total number of applicants due to the fact the launch of

Simio Announces Winners of the Simio Scholar Simulation December 2020 Competitiveness

PITTSBURGH, Jan. 14, 2021 /PRNewswire/ — The Simio College student Simulation Competition is a bi-yearly function committed to undergraduate and graduate groups throughout the earth participating in simulation modeling and scheduling coursework. The Simio Pupil Level of competition is the industry’s leading level of competition for pupils, and it prepares college students for the application of simulation technological know-how to resolve intricate genuine-entire world problems in groups of not a lot more than four people.

Every year, Simio outlines the regulations and laws for participation together with a challenge overview which collaborating pupil groups ought to resolve to gain fantastic prizes. The December 2020 Competition dilemma targeted on a Barbecue Pit or cafe going through weak provider stages thanks to insufficient inventory administration and long hold out instances. Contestants had been tasked with optimizing the restaurant’s support ranges by means of optimized stock administration, scheduling, and fixing staffing bottlenecks

Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies

Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC

Phase 3 Studies for DTX401 and DTX301 to Begin in 2021

IND for UX701 for Wilson Disease Submitted; Expect to Enter Clinic in First Half 2021 using AAV Drug Product Made by HeLa PCL Platform

NOVATO, Calif. , Jan. 08, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 studies of DTX401, an investigational adeno-associated virus (AAV) gene therapy for Glycogen Storage Disease Type Ia (GSDIa), and DTX301, an AAV gene therapy for ornithine transcarbamylase (OTC) deficiency. In addition, dosing is nearing completion for the prophylactic steroid cohorts in both studies. Discussions with regulatory agencies continue to

tastyworks Announces Breakthrough in Brokerage Technologies

tastyworks, the revolutionary chief in retail brokerage technologies, currently introduced the launch of its new characteristic that lets comprehensive effectiveness tracking of advanced stock and selection tactics. Buy-Chains (patent pending) allows traders see the profit and decline on combinations of open and closed positions instantly, in actual-time.

tastyworks continues to deliver next-gen investing resources for the gain of its swiftly escalating customer base. Purchase-Chains removes the need to have for spreadsheets or 3rd-celebration software that involve handbook enter, and radically raises the pace of the trade conclusion procedure.

“What separates tastyworks from its competitiveness is that they really do pay attention to their prospects. They questioned for a way for the platform to do what they are performing by hand – calculate the financial gain or loss on positions they’ve altered or closed in conjunction with open up positions – and tastyworks sent. The new Buy-Chains instrument is now

Emulate Announces Lung-Chip Technologies Made use of by U.S. Military to Examine Effects of COVID-19

BOSTON, Dec. 8, 2020 /PRNewswire/ — Emulate, Inc., a top service provider of state-of-the-art in vitro types, right now announced that its Alveolus Lung-Chip is remaining applied by the U.S. Military to comprehend how the SARS-CoV-2 virus interacts with lung cells. With funding from the FY20 Coronavirus Aid, Aid, and Economic Protection (CARES) Act, scientists at the U.S. Army Fight Abilities Advancement Command (DEVCOM) Chemical Organic Center are making use of Emulate Lung-Chips to observe intracellular interactions and greater understand the function of proteins within just lung cells on ailment procedures.

Emulate Lung-Chip models recreate key facets of pulmonary physiology by incorporating several main cell styles in distinctive epithelial and vascular channels in a lung-precise dynamic microenvironment which can mimic tissue-to-tissue interactions, extracellular matrix, immune cell elements and mechanical forces. They are best for scientific studies hunting at viral an infection and pathogenesis and efficacy tests.  

“In the earlier,

Avacta Team announces important progress in the enhancement of SARS-CoV-2 swift antigen check

Avacta Team plc, the developer of impressive most cancers therapies and diagnostics primarily based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant development in the progress of a hugely scalable production process for a lateral movement SARS-CoV-2 antigen check being carried out with BBI Alternatives, and that the lateral movement take a look at has pretty good analytical sensitivity with laboratory samples.

Avacta is acquiring many coronavirus checks applying Affimer binders that are really unique to the SARS-CoV-2 virus spike protein.

The development of an Affimer-dependent lateral stream antigen examination that can be produced at scale staying carried out in partnership with BBI Methods has manufactured sizeable development. A extremely scalable test device utilizing readily offered parts and program production processes has now been proven to have a sensitivity for coronavirus spike protein in laboratory samples much better than 300 pg/ml which

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

SAN DIEGO–(BUSINESS WIRE)–
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin pump with Control-IQ™ technology. Control-IQ technology is an advanced hybrid closed-loop feature designed to help increase time in range (3.9-10 mmol/L)1 and deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. The system integrates with Dexcom G6 continuous glucose monitoring (CGM), which requires no fingersticks for calibration or diabetes treatment decisions.2,3,4

All in-warranty t:slim X2 pump users in Canada will have the option to add Control-IQ technology to their existing pump beginning in March 2021 via remote software update. The update will be free of charge through December 31, 2021.5 Tandem expects to begin shipping t:slim X2 insulin pumps with Control-IQ technology in Canada in the first quarter of next year. The company